Compare SHC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHC | TNGX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.5B |
| IPO Year | 2020 | 2020 |
| Metric | SHC | TNGX |
|---|---|---|
| Price | $18.85 | $27.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $20.33 | ★ $21.78 |
| AVG Volume (30 Days) | ★ 2.9M | 2.0M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.75 | 26.89 |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,163,617,000.00 | $62,384,000.00 |
| Revenue This Year | $7.51 | N/A |
| Revenue Next Year | $6.00 | N/A |
| P/E Ratio | $210.11 | ★ N/A |
| Revenue Growth | 5.74 | ★ 48.29 |
| 52 Week Low | $13.09 | $6.25 |
| 52 Week High | $19.85 | $34.39 |
| Indicator | SHC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 67.80 | 53.56 |
| Support Level | $15.11 | $27.79 |
| Resistance Level | $19.85 | $33.96 |
| Average True Range (ATR) | 0.50 | 1.59 |
| MACD | 0.05 | 0.11 |
| Stochastic Oscillator | 87.58 | 74.59 |
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.